N-(7-amino-naphthalen-1-yl)-N'-(4-chloro-3-trifluoromethyl-phenyl)urea | 497149-13-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(7-amino-naphthalen-1-yl)-N'-(4-chloro-3-trifluoromethyl-phenyl)urea
• 英文别名: N-(7-amino-1-naphthyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea；1-(7-Aminonaphthalen-1-yl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
• CAS: 497149-13-0
• 化学式: C₁₈H₁₃ClF₃N₃O
• 分子量: 379.769
• InChiKey: SNCPMZFTUZCFRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  67.2
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(7-amino-naphthalen-1-yl)-N'-(4-chloro-3-trifluoromethyl-phenyl)urea 在 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以17%的产率得到1-(7-Amino-6-chloronaphthalen-1-yl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
  参考文献：
  名称：

  Tetrahydro-naphthols as orally available TRPV1 inhibitors

  摘要：

  Starting from a naphthol-based lead series with low oral bioavailability, we have identified potent TRPV1 antagonists with oral bioavailability in rats. These compounds emerged from SAR studies aimed at replacing the lead's phenol structure whilst maintaining potency. Compound rac-6a is an orally available TRPV1 antagonist with single-digit nanomolar activity. The enantiomers show a low eudismic ratio at the receptor level. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.108

文献信息

• [EN] NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS<br/>[FR] DERIVES AMINES
  申请人：BAYER AG

  公开号：WO2003014064A1

  公开（公告）日：2003-02-20

  Naphthylurea and naphthylacetamide derivatives of formula (I) which have vanilloid receptor 1 (VR1) antagonistic activity are disclosed, formula (I) wherein Y represents formula (II) and formula (III) and the variables Q, X, R6, R7, R8, R8a, R9, R10 and R11 are as defined in the claims. The compounds are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  本文披露了公式(I)的萘基脲和萘基乙酰胺衍生物，其具有vanilloid受体1（VR1）拮抗活性，其中公式(I)中Y代表公式(II)和公式(III)，而变量Q、X、R6、R7、R8、R8a、R9、R10和R11如权利要求中所定义。这些化合物可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、过度活动膀胱、慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病。
• Amine derivatives
  申请人：——

  公开号：US20040259875A1

  公开（公告）日：2004-12-23

  An amine derivative, its tautomeric or stereoisomeric form, or a salt thereof which has vanilloid receptor 1 (VR1) antagonistic activity, is disclosed. The amine derivative has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  本发明揭示了一种具有vanilloid receptor 1（VR1）拮抗活性的胺衍生物、其互变异构体或立体异构体形式或其盐。该胺衍生物具有优异的VR1拮抗活性，适用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、过度活动膀胱、慢性疼痛、神经痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病。
• NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS
  申请人：Bayer HealthCare AG

  公开号：EP1414788A1

  公开（公告）日：2004-05-06